Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 3/2017

Open Access 01-03-2017 | Editorial

The oncology day hospital in Spain: an updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward

Authors: C. Jara, F. Ayala, J. A. Virizuela, Oncology Day Hospital Task Force

Published in: Clinical and Translational Oncology | Issue 3/2017

Login to get access

Excerpt

The day hospital is the unit of care where, under a specialist physician’s supervision or indication, patients undergoing complex diagnostic methods or treatment requiring hours of continuous medical and/or nursing care, but not hospital admission, are treated or receive care [1]. Day hospitals arose from the experience in hematology in the USA in the 1970s. Patients with leukemias and lymphomas needed complex treatments, in addition to transfusions, which entailed frequent care at the hospital. Hospitalization, with the implications it had for these patients’ quality of life and high associated costs, could be avoided with these new care units. The rationale for the monographic oncology day hospital (ODH) is that cancer patient care accounts for 80% of the activity at general day hospitals and calls for a well-defined diagnostic and therapeutic care; furthermore, unlike other specialties, cancer patients’ care demand is usually scheduled. …
Literature
1.
Ministerio de Sanidad y Consumo. Real Decreto 1277/2003, de 10 de octubre, por el que se establecen las bases generales sobre autorización de centros, servicios y establecimientos sanitarios. 2003.
2.
Jara Sánchez C. Ayala de la Peña F, Virizuela-Echaburu JA (eds). Sociedad Española de Oncología Médica: Hospitales de día en oncología; 2015.
3.
Casas Fernández de Tejerina AM, Moreno Nogueira JA. Hospitales de día: recomendaciones según consenso nacional SEOM Madrid marzo 2006. In: Aranda Aguilar E BOM, Casas Fernández de Tejerina AM, Felip Font E, Garrido López MP, Rifá Ferrer J, editor. Libro Blanco de la Oncología Médica en España. Madrid: Sociedad Española de Oncología; 2007.
4.
Kuperman GJ, Gibson RF. Computer physician order entry: benefits, costs, and issues. Ann Intern Med. 2003;139:31–9.CrossRefPubMed
5.
Shulman LNMR, Ambinder EP, Yu PP, Cox JV. Principles of safe practice using an oncology EHR system for chemotherapy ordering, preparation, and administration, part 1 of 2. J Oncol Pract. 2008;4:203–6.CrossRefPubMedCentral
6.
Aranaz Andrés JM (2006) Estudio Nacional sobre los Efectos Adversos ligados a la Hospitalización. ENEAS 2005.
7.
Goodin S, Griffith N, Chen B, Chuk K, Daouphars M, Doreau C, et al. Safe handling of oral chemotherapeutic agents in clinical practice: recommendations from an international pharmacy panel. J Oncol Pract. 2011;7:7–12.CrossRefPubMedPubMedCentral
8.
Neuss MN, Polovich M, McNiff K, Esper P, Gilmore TR, LeFebvre KB, et al. 2013 updated American Society of Clinical Oncology/Oncology Nursing Society chemotherapy administration safety standards including standards for the safe administration and management of oral chemotherapy. J Oncol Pract. 2013;9(2 Suppl):5s–13s.CrossRefPubMedPubMedCentral
9.
Coriat R, BouODH-Rouquette P, Durand JP, Forgeot d’Arc P, Martin I, Mir O, et al. Cost effectiveness of integrated medicine in patients with cancer receiving anticancer chemotherapy. J Oncol Pract. 2012;8:205–10.CrossRefPubMedPubMedCentral
10.
Kane B, Sands DZ. Guidelines for the clinical use of electronic mail with patients. The AMIA Internet Working Group, Task Force on Guidelines for the Use of Clinic-Patient Electronic Mail. J Am Med Inform Assoc. 1998;5:104–11.CrossRefPubMedPubMedCentral
11.
Bielli E, Carminati F, La Capra S, Lina M, Brunelli C, Tamburini M. A Wireless Health Outcomes Monitoring System (WHOMS): development and field testing with cancer patients using mobile phones. BMC Med Inform Decis Mak. 2004;4:7.CrossRefPubMedPubMedCentral
12.
Basch E, Artz D, Iasonos A, Speakman J, Shannon K, Lin K, et al. Evaluation of an online platform for cancer patient self-reporting of chemotherapy toxicities. J Am Med Inform Assoc. 2007;14:264–8.CrossRefPubMedPubMedCentral
13.
Judson TJ, Bennett AV, Rogak LJ, Sit L, Barz A, Kris MG, et al. Feasibility of long-term patient self-reporting of toxicities from home via the Internet during routine chemotherapy. J Clin Oncol. 2013;31:2580–5.CrossRefPubMedPubMedCentral
14.
Chih MY, DuBenske LL, Hawkins RP, Brown RL, Dinauer SK, Cleary JF, et al. Communicating advanced cancer patients’ symptoms via the Internet: a pooled analysis of two randomized trials examining caregiver preparedness, physical burden, and negative mood. Palliat Med. 2013;27:533–43.CrossRefPubMed
Metadata
Title
The oncology day hospital in Spain: an updated analysis of Spanish Society of Medical Oncology (SEOM) looking forward
Authors
C. Jara
F. Ayala
J. A. Virizuela
Oncology Day Hospital Task Force
Publication date
01-03-2017
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 3/2017
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-016-1610-1

Other articles of this Issue 3/2017

Clinical and Translational Oncology 3/2017 Go to the issue

Review Article

Consensus on the management of advanced radioactive iodine-refractory differentiated thyroid cancer on behalf of the Spanish Society of Endocrinology Thyroid Cancer Working Group (GTSEEN) and Spanish Rare Cancer Working Group (GETHI)

Research Article

Mid-term oncologic outcome of a novel approach for locally advanced colon cancer with neoadjuvant chemotherapy and surgery

Research Article

Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib

Research Article

Salvage treatment with irinotecan/cisplatin versus pemetrexed/cisplatin in patients with non-small cell lung cancer pre-treated with a non-platinum-based regimen in the first-line setting: a randomized phase II study of the Hellenic Oncology Research Group (HORG)

Special Article

European edition of the NCCN clinical practice guidelines: relevance of the translation and adaptation into Spanish

Research Article

Incidence and survival time trends for Spanish children and adolescents with leukaemia from 1983 to 2007
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits